Mirum’s Q2 2026 Playbook: Revenue Forecast Raised on Pipeline Momentum

Ticker: MIRM. In this update, the focus is on EPS visibility, revenue forecast shifts, and a string of regulatory milestones that could reframe the long game for Mirum Pharmaceuticals.

Snapshot: numbers, guidance, and the lack of an immediate EPS story

Mirum Pharmaceuticals, Inc. (MIRM) reports a quarter centered on topline momentum rather than a clean earnings-per-share beat. Net product sales for the second quarter of 2026 came in at $176 million, with LIVMARLI contributing $128.7 million — up a substantial 46% versus the same period last year. The company raised its full-year net product sales guidance to $680 million to $700 million, signaling confidence in near-term revenue trajectory.

As for traditional income metrics, the release does not present an EPS figure. Investors watching for an EPS consensus and potential earnings surprise will need to wait for future filings or accompanying quarterly results. In other words, the core narrative here is top-line strength and a path to profitability that remains dependent on regulatory milestones and later-stage data rather than an immediate per-share print.

Regulatory momentum and pipeline milestones

Volixibat has been granted Breakthrough Therapy and Orphan Drug Designations for the treatment of cholestatic pruritus due to primary sclerosing cholangitis (PSC).
A pre-NDA meeting with the U.S. FDA proceeded with constructive discussions; Mirum plans additional interactions before a potential NDA submission, now targeted for the first half of 2027, contingent on VISTAS data.
Enrollment in the VANTAGE Phase 2b study of volixibat in cholestatic pruritus due to PBC has been completed; topline results are expected in Q1 2027.
AZURE-1 and AZURE-4 Phase 3 studies in chronic hepatitis delta virus (HDV) topline results are anticipated in Q3 and Q4 2026, respectively.
LIVMARLI Expand Phase 3 study in additional rare cholestatic conditions is expected to yield topline results in Q4 2026.
Mirum will host a conference call today, August 5, at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and strategy.

The mix of strong quarterly LIVMARLI performance with an actively evolving regulatory roadmap creates a narrative where the stock’s near-term trajectory hinges on NDA timing and trial toplines as much as any single quarterly earnings number.

What this portends for Mirum and sector peers

The revenue forecast lift underscores a more confident revenue trajectory, particularly as LIVMARLI continues to drive the company’s short-run top line. The Breakthrough Therapy and Orphan Drug designations add optionality and regulatory optionality, which can compress the time to market for new indications and create optional value for investors, even if the company remains unprofitable on a reported EPS basis today.

For sector peers, the message is twofold: a) a diversified pipeline that includes both a late-stage product (LIVMARLI) with durable growth and early-to-mid-stage assets (volixibat, BREL, and HDV programs) can sustain multiple catalysts; and b) the timing of NDA submissions and pivotal readouts increasingly drives equity narratives more than quarterly profit prints. In a space where many names are still counting on regulatory Okay or Phase 3 readouts to justify valuation, Mirum’s blend of commercial momentum and regulatory cadence provides a useful blueprint—and a reminder that the “earnings surprise” for many biotechs may emerge not from a single quarter’s earnings but from a sequence of data reads and approvals.

Analyst take: how the pieces fit together

The reported Q2 numbers show real, defensible growth in net product sales, with LIVMARLI contributing materially to the revenue base and growth rate. The revenue forecast upgrade signals that management expects continued strength, which could support a more favorable view of the company’s earnings trajectory down the line. However, the absence of an explicit EPS figure means the market will likely calibrate expectations around future quarters’ profitability and the structure of R&D spending as the NDA path unfolds.

From a peer perspective, Mirum’s trajectory suggests that success in this sector hinges on a combination of commercial execution, regulatory timing, and the ability to translate trial results into additional indications. The HDV topline expectations and the PSC-related designations present a framework in which other rare-disease players might seek to accelerate or de-risk their own programs through regulatory designations and strategic sequencing of readouts.

In terms of potential earnings surprises, any upside would likely come from stronger-than-expected topline performance or earlier-than-anticipated NDA activity that accelerates approvals and, by extension, revenue recognition. For investors watching EPS consensus, the key questions remain: will future quarters deliver an EPS print that aligns with or exceeds consensus, and how quickly can the company translate its expanding pipeline into durable profitability?

What the CEO’s view signals

CEO Chris Peetz framed the quarter as momentum-driven, highlighting the strength of the VISTAS data and the agency’s direction on next steps. The stance signals patience with regulatory processes paired with an ambition to convert clinical milestones into tangible value. That balance—commercial growth coupled with disciplined regulatory pacing—will be the real determinant of how Mirum’s equity story evolves over the next 12 to 18 months.

Event note

The company’s conference call is scheduled for today, August 5, at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and strategic outlook.